A Form 4 filed on August 26, 2026 reports that Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (NASDAQ:TXG), disposed of 17,166 shares of Class A Common Stock on August 24, 2026 to cover tax withholding obligations tied to the vesting of restricted …
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), filed a Form 4 on August 26, 2026, reporting the sale of Class A Common Stock on August 24, 2026, to cover tax withholding obligations connected to the vesting of restricted …
A Form 4 filed on August 26, 2026 with the U.S. Securities and Exchange Commission shows Steven D. Gray, a director of Permian Resources Corp (NYSE:PR), disposed of 24,000 shares of Class A Common Stock through a gift transaction on August 26, 2026.
Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc., filed a Form 4 on August 26, 2026, reporting the sale of 18,545 shares of Class A Common Stock on August 24, 2026, to cover tax withholding obligations connected to the vesting of …
A Form 4 filed on August 26, 2026, disclosed that Robert M. Tichio, a director of Permian Resources Corp (NYSE:PR), disposed of a combined 7,200 shares of Class A Common Stock on August 24, 2026, through two gift transactions at $0 per share.
George P. Sakellaris, Chief Executive Officer and Director of Ameresco, Inc. (NASDAQ:AMRC), filed a Form 4 on August 26, 2026, disclosing open-market purchases of 10,000 shares of Class A Common Stock across three transactions on August 24 and August 25, 2026.
Warren B. Kanders, CEO, Chairman, and a 10% owner of Cadre Holdings, Inc. (NYSE:CDRE), filed a Form 4 on August 26, 2026, disclosing the sale of 200,000 shares of common stock through Kanders SAF, LLC across August 24 and August 25, 2026.
Director Joseph W. Sutton filed a Form 4 with the SEC on August 26, 2026, disclosing an open-market purchase of 9,700 shares of Ameresco, Inc. (NYSE:AMRC) Class A Common Stock on August 24, 2026.
A Form 4 filed with the SEC on August 26, 2026, discloses that Jennifer L. Miller, a director of Ameresco, Inc. (NYSE:AMRC), purchased 2,000 shares of Class A Common Stock on August 24, 2026.
Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), filed a Form 4 on August 26, 2026, disclosing the sale of 3,035 shares of common stock on August 24, 2026, pursuant to a Rule 10b5-1 automatic sale instruction to satisfy tax withholding obligations.